03:00 AM EDT, 10/30/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our 12-month target to $180 from $175, valuing shares at 21x our 2026 EPS view of $8.58 (down from $8.63; 2025 EPS cut to $7.91 from $8.00). IEX exceeded Q3 expectations with operating EPS of $2.03, beating consensus by $0.10, while sales rose 10% Y/Y (+5% organic) led by growth in two of three segments. The Health & Science Tech segment was the standout performer, delivering 22% Y/Y sales growth (+10% organic) and 120 bps of adjusted EBITDA margin expansion, benefiting from momentum in data centers, space & defense, life sciences, and semiconductors. We view IEX's results as encouraging overall, with HST's performance validating the company's strategic pivot toward higher-growth, technology-enabled markets with secular tailwinds. However, management cut full-year 2025 adjusted EPS guidance to $7.86-$7.91 from $8.10-$8.45 while maintaining ~1% organic revenue growth expectations, reflecting additional tariff pressures expected in Q4.